Forecasting The Future: 5 Analyst Projections For Liquidia

5 analysts have shared their evaluations of Liquidia LQDA during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $28.8, with a high estimate of $32.00 and a low estimate of $28.00. A decline of 1.81% from the prior average price target is evident in the current average.

Understanding Analyst Ratings: A Comprehensive Breakdown

A clear picture of Liquidia's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Liquidia. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Liquidia compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Liquidia's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Liquidia's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Liquidia analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

About Liquidia

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Liquidia's Financial Performance

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Negative Revenue Trend: Examining Liquidia's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -33.85% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Liquidia's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1377.12%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Liquidia's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -61.29%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Liquidia's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -25.95%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Liquidia's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.